Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Wexler

Showing results (261-270 of 418) with videos related to

Pageof 42
Sort By:
Annals of Plastic Surgery|February 1, 1996
Chest wall deformity following maximal tissue expansion for breast reconstructionE V Moor, M R Wexler, Y Bar-Ziv, et al.
Journal of Thrombosis and Haemostasis : JTH|March 5, 2008
Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studiesP C Wong, E J Crain, B Xin, et al.
Medicinal Research Reviews|March 1, 1992
The discovery of DuP 753, a potent, orally active nonpeptide angiotensin II receptor antagonistJ V Duncia, D J Carini, A T Chiu, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1991
Pharmacology of DuP 532, a selective and noncompetitive AT1 receptor antagonistP C Wong, S D Hart, A T Chiu, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 1, 1990
Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agentP C Wong, W A Price, A T Chiu, et al.
Bioorganic & Medicinal Chemistry Letters|January 1, 1999
Rational design of boropeptide thrombin inhibitors: beta, beta-dialkyl-phenethylglycine P2 analogs of DuP 714 with greater selectivity over complement factor I and an improved safety profileJ M Fevig, J Buriak, J Cacciola, et al.
Journal of Medicinal Chemistry|May 19, 2018
Factor XIa Inhibitors as New AnticoagulantsMimi L Quan, Donald J P Pinto, Joanne M Smallheer, et al.
Journal of Thrombosis and Haemostasis : JTH|November 9, 2021
Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbitsPancras C Wong, Earl J Crain, Jeffrey M Bozarth, et al.
Bioorganic & Medicinal Chemistry Letters|April 18, 2015
Design and synthesis of potent, selective phenylimidazole-based FVIIa inhibitorsPeter W Glunz, Xuhong Cheng, Daniel L Cheney, et al.
Journal of Medicinal Chemistry|October 14, 1994
Acyl CoA:cholesterol acyltransferase (ACAT) inhibitors: synthesis and structure-activity relationship studies of a new series of trisubstituted imidazolesC A Higley, R G Wilde, T P Maduskuie, et al.
Pageof 42

Showing results (261-270 of 418) with videos related to

Sort By:
Pageof 42
Annals of Plastic Surgery|February 1, 1996
Chest wall deformity following maximal tissue expansion for breast reconstructionE V Moor, M R Wexler, Y Bar-Ziv, et al.
Journal of Thrombosis and Haemostasis : JTH|March 5, 2008
Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studiesP C Wong, E J Crain, B Xin, et al.
Medicinal Research Reviews|March 1, 1992
The discovery of DuP 753, a potent, orally active nonpeptide angiotensin II receptor antagonistJ V Duncia, D J Carini, A T Chiu, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1991
Pharmacology of DuP 532, a selective and noncompetitive AT1 receptor antagonistP C Wong, S D Hart, A T Chiu, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 1, 1990
Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agentP C Wong, W A Price, A T Chiu, et al.
Bioorganic & Medicinal Chemistry Letters|January 1, 1999
Rational design of boropeptide thrombin inhibitors: beta, beta-dialkyl-phenethylglycine P2 analogs of DuP 714 with greater selectivity over complement factor I and an improved safety profileJ M Fevig, J Buriak, J Cacciola, et al.
Journal of Medicinal Chemistry|May 19, 2018
Factor XIa Inhibitors as New AnticoagulantsMimi L Quan, Donald J P Pinto, Joanne M Smallheer, et al.
Journal of Thrombosis and Haemostasis : JTH|November 9, 2021
Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbitsPancras C Wong, Earl J Crain, Jeffrey M Bozarth, et al.
Bioorganic & Medicinal Chemistry Letters|April 18, 2015
Design and synthesis of potent, selective phenylimidazole-based FVIIa inhibitorsPeter W Glunz, Xuhong Cheng, Daniel L Cheney, et al.
Journal of Medicinal Chemistry|October 14, 1994
Acyl CoA:cholesterol acyltransferase (ACAT) inhibitors: synthesis and structure-activity relationship studies of a new series of trisubstituted imidazolesC A Higley, R G Wilde, T P Maduskuie, et al.
Pageof 42